Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: A role for the JAK2 V617F mutation re-evaluation

Thrombosis Research

Volumn 132, Issue 2, 2013, Pages

  Colaizzo, Donatella ^a   Amitrano, Lucio ^b   Guardascione, Maria Anna ^b   Tiscia, Giovanni Luca ^a   D'Andrea, Giovanna ^c   Longo, Vittoria A C ^c   Grandone, Elvira ^a   Margaglione, Maurizio ^c  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Mutation; Myeloproliferative disease; Risk factors; Splanchnic circulation; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; JANUS KINASE 2;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EVALUATION; FEMALE; GENE MUTATION; HUMAN; MALE; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; TREATMENT OUTCOME; VEIN THROMBOSIS;

MUTATION; MYELOPROLIFERATIVE DISEASE; RISK FACTORS; SPLANCHNIC CIRCULATION; VENOUS THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; RISK FACTORS; SPLANCHNIC CIRCULATION; TREATMENT OUTCOME; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84883829429     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.07.014     Document Type: Article

References (39)

1. M.H. Denninger, Y. Chait, N. Casadevall, S. Hillaire, M.C. Guillin, and A. Bezeaud Cause of portal or hepatic vein thrombosis in adults: the role of multiple concurrent factors Hepatology 31 2000 587 591
2. Gruppo Italiano Studio Policitemia Polycythemia vera: the natural history of 1213 patients followed for 20 years Ann Intern Med 123 1995 656 664
3. V. De Stefano, T. Za, E. Rossi, M. Ruggeri, E. Elli, and C. Micò Recurrent thrombosis in pa- tients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments Haematologica 93 2008 372 380
4. A. Plessier, S. Darwish-Murad, M. Hernandez-Guerra, Y. Consigny, F. Fabris, and J. Trebicka Acute portal vein thrombosis unrelated to cirrhosis: a pro- spective multicenter follow-up study Hepatology 51 2010 210 218
5. C.M. Kessler Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders Semin Hematol 41 2 Suppl. 3 2004 10 14
6. F. Passamonti, E. Rumi, E. Pungolino, L. Malabarba, P. Bertazzoni, and M. Valentini Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia Am J Med 117 2004 755 761
7. E.J. Baxter, L.M. Scott, P.J. Campbell, C. East, N. Fourouclas, and S. Swanton Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 9464 2005 1054 1061
8. R. Kralovics, F. Passamonti, A.S. Buser, S.S. Teo, R. Tiedt, and J.R. Passweg A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 17 2005 1779 1790
9. F. Dentali, A. Squizzato, L. Brivio, L. Appio, L. Campiotti, and M. Crowther JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis Blood 113 22 May 28 2009 5617 5623
10. J.H. Smalberg, L.R. Arends, D.C. Valla, J.J. Kiladjian, H.L. Janssen, and F.W. Leebeek Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis Blood 120 25 Dec 13 2012 4921 4928
11. H.L.A. Janssen, A. Wijnhoud, E.B. Haagsma, S.H.M. van Uum, C.M.J. van Nieuwkerk, and R.P. Adang Extrahepatic portal vein thrombosis: aetiology and determinants of survival Gut 49 2001 720 724
12. V. De Stefano, A. Fiorini, E. Rossi, T. Za, G. Farina, and P. Chiusolo Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders J Thromb Haemost 5 2007 708 714
13. C. James, V. Ugo, J.P. Le Couedic, J. Staerk, F. Delhommeau, and C. Lacout A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 2005 1144 1148
14. A. Falanga, M. Marchetti, V. Evangelista, A. Vignoli, M. Licini, and M. Balicco Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera Blood 96 2000 4261 4266
15. M. Marchetti, E. Castoldi, H.M. Spronk, R. van Oerle, D. Balducci, and T. Barbui Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera Blood 112 2008 4061 4068
16. M. Primignani, G. Barosi, G. Bergamaschi, U. Gianelli, F. Fabris, and R. Reati Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis Hepatology 44 2006 1528 1534
17. D. Colaizzo, L. Amitrano, G.L. Tiscia, G. Scenna, E. Grandone, and M.A. Guardascione The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis J Thromb Haemost 5 2007 55 61
18. F. Passamonti, M. Maffioli, M. Merli, A. Ferrario, and D. Caramazza Clinical predictors of outcome in MPN Hematol Oncol Clin North Am 26 2012 1101 1116
19. F. Cardin, M. Graffeo, P.A. McCormick, N. McIntyre, and A. Burroughs Adult "idiopathic" extrahepatic venous thrombosis. Importance of putative "latent" myeloproliferative disorders and comparison with cases with known etiology Dig Dis Sci 37 1992 335 339
20. A. Tefferi, and J.W. Vardiman Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms Leukemia 22 2008 14 22
21. P.R. Ames, C. Tommasino, G. D'Andrea, L. Iannaccone, V. Brancaccio, and M. Margaglione Thrombophilic genotypes in subjects with idiopathic antiphospholipid antibodies-prevalence and significance Thromb Haemost 79 1998 46 49
22. L. Amitrano, V. Brancaccio, M.A. Guardascione, M. Margaglione, L. Iannaccone, and G. D'Andrea High prevalence of thrombophilic genotypes in patients with acute mesenteric vein thrombosis Am J Gastroenterol 96 2001 146 149
23. J.J. Kiladjian, F. Cervantes, F.W. Leebeek, C. Marzac, B. Cassinat, and S. Chevret The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases Blood 111 2008 4922 4929
24. R. Marchioli, G. Finazzi, R. Landolfi, J. Kutti, H. Gisslinger, and C. Patrono Vascular and neoplastic risk in a large cohort of patients with polycythemia vera J Clin Oncol 23 2005 2224 2232
25. S. Cortelazzo, P. Viero, G. Finazzi, A. D'Emilio, F. Rodeghiero, and T. Barbui Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia J Clin Oncol 8 1990 556 562
26. J. Hoekstra, E.L. Bresser, J.H. Smalberg, M.C. Spaander, F.W. Leebeek, and H.L. Janssen Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms J Thromb Haemost 9 2011 2208 2214
27. R. Jäger, and R. Kralovics Molecular basis and clonal evolution of myeloproliferative neoplasms Haematologica 95 2010 526 529
28. A. Carobbio, G. Finazzi, V. Guerini, O. Spinelli, F. Delaini, and R. Marchioli Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status Blood 109 2007 2310 2313
29. R. Landolfi, L. Di Gennaro, T. Barbui, V. De Stefano, G. Finazzi, and R. Marfisi Leukocytosis as a major thrombotic risk factor in patients with Polycythemia Vera Blood 109 2007 2446 2452
30. S. Sozer, M.I. Fiel, T. Schiano, M. Xu, J. Mascarenhas, and R. Hoffman The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome Blood 113 2009 5246 5249
31. L. Teofili, M. Martini, M.G. Iachininoto, S. Capodimonti, E.R. Nuzzolo, and L. Torti Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms Blood 117 2011 2700 2707
32. V. Rosti, L. Villani, R. Riboni, V. Poletto, E. Bonetti, and L. Tozzi Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation Blood 121 2013 360 368
33. X. Xu, Q. Zhang, J. Luo, S. Xing, Q. Li, and S.B. Krantz JAK2(V617F): Prevalence in a large Chinese hospital population Blood 109 2007 339 342
34. N.C. Cross Genetic and epigenetic complexity in myeloproliferative neoplasms Hematology Am Soc Hematol Educ Program 2011 2011 208 214
35. B. Condat, F. Pessione, S. Hillaire, M.H. Denninger, M.C. Guillin, and M. Poliquin Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy Gastroenterology 120 2001 490 497
36. F. Dentali, W. Ageno, D. Witt, A. Malato, N. Clark, and D. Garcia Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: A multi-centre, retrospective cohort study Thromb Haemost 102 2009 501 504
37. M.R. Thatipelli, R.D. McBane, D.O. Hodge, and W.E. Wysokinski Survival and Recurrence in Patients With Splanchnic Vein Thromboses Clin Gastroenterol Hepatol 8 2010 200 205
38. M. Ruggeri, H. Gisslinger, A. Tosetto, C. Rintelen, C. Mannhalter, and I. Pabinger Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia Am J Hematol 71 2002 1 6
39. A.H. Schmitt-Graeff, S.S. Teo, M. Olschewski, F. Schaub, S. Haxelmans, and A. Kirn JAK2V617F mutation status identifies subtypes of refractory anaemia with ringed sideroblasts associated with marked thrombocytosis Haematologica 93 2008 34 40